FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Buy Recommendation On Shares Of Alibaba Group Holding Limited

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our 12-month target to USD184 from USD163, on a P/E of about 15x (unchanged) our FY 28 (Mar.) EPS of USD12.26 (based on current FX), which is within its long-term range. We trim our FY 27 EPS to CNY53.65 from CNY 56.81 but raise FY 28 to CNY83.23 from CNY74.64. We expect cloud revenue growth to accelerate from roughly 40% in the latest quarter to 47% in FY 27, fueled by AI-related revenue, which currently accounts for about 30% of the cloud business and should rise to 50% within the next year. We also expect BABA to see a meaningful profit inflection over the next several years as losses in quick commerce narrow substantially and AI-related investments become increasingly monetized. Cloud margins were just 9% this past fiscal year but should improve materially over the coming quarters, particularly as the high-margin MaaS (model-as-a-service) business scales. We continue to view BABA shares as the most compelling way to gain exposure to the AI theme in China.

Related Articles

Research

Research Alert: CFRA Lowers Rating On Shares Of Medtronic Plc To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We cut our target to $83 from $118, 13.7x our FY 27 (Apr.) EPS view, below MDT's 10-year historical forward average of 17.6x. We trim our FY 26 EPS estimate to $5.52 from $5.65 due to lower profitability expectations and MiniMed IPO dilution. We cut our FY 27 view to $6.06 from $6.11. We downgrade shares to Hold from Buy following a mixed Q1 MedTech earnings season, with divergent performances across companies and multiple near-term headwinds, including margin pressures from rising raw material costs, supply chain challenges, and tariffs, which we think can also impact MDT. Adding to these pressures, MDT announced (May 11) the closure of its Santa Rosa, CA facility, which faced a $381M antitrust verdict in February. Also, the China business (~10% of total revenue) has been facing challenges from aggressive anti-corruption campaigns targeting health care and government volume-based procurement policies, triggering steep price cuts on medical devices, with limited near-term visibility on normalization.

$MDT
Research

CCL Industries Target Raised To C$104 From $102, Keeps Outperform at National Bk; Notes Q1 Revs In Line, EBITDA Slightly Better, Optimistic Outlook, Layering In NCIB Assumptions

Price: $86.86, Change: $+2.40, Percent Change: +2.84%

$CCL-A.TO$CCL-B.TO
Research

Research Alert: CFRA Maintains Hold Opinion On Ads Of Honda Motor Co., Ltd

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We revise our 12-month target price to USD26 (from USD25), which implies a forward P/E of 9.7x based on our revised FY 27 (Mar.) EPS estimate of JPY423 (up from JPY297). We also initiate our FY 28 EPS estimate of JPY579. Our upward revision reflects a clearer near-term earnings trough following Honda's decisive reassessment of its automobile electrification strategy, which resulted in total EV-related losses in FY 26 but allows the company to focus on its profitable hybrid electric vehicle (HEV) and motorcycle operations. The motorcycle business continues to deliver record-high sales volumes and operating profit, supported by strong demand in India and Brazil, while the automobile business is projected to benefit from a renewed focus on HEVs, particularly in North America, where the company plans to increase production and introduce new models. Honda's sound financial foundation supports a stable dividend.

$HMC